Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

JRNYS vs KERNX Health

JRNYS
Graded #267

Higher grade

vs+0.29999999999999716
KERNX Health
Graded #276

Lower grade

The verdict

JRNYS takes it — 62.5/100 to 62.2/100, but only just.

JRNYS grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. JRNYS is a telehealth weight-loss membership built around branded GLP-1 medications, and the membership itself buys no medication. KERNX Health is close behind and may still be the better fit — see the factor split below.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueKERNX Health +17
45
62
Dose & formulationKERNX Health +6
58
64
Clinical oversightJRNYS +13
84
71
Labs & monitoringJRNYS +19
71
52
FulfillmentKERNX Health +4
65
69
Contract termsJRNYS +10
55
45
JRNYS · left barKERNX Health · right bar

The numbers

MetricJRNYSKERNX Health
WeighScore62.5/10062.2/100
GradeCC
Scorecard rank#267#276
SemaglutideNot disclosed$129/mo (promotional rate, plus a separate fee, compounded)
TirzepatideNot disclosed$199/mo (promotional rate, plus a separate fee, compounded)
CoverageCoverage not publishedCoverage not published
Brand-name accessYesCompounded only
Oral / sublingualInjection onlyInjection only
JRNYS

Graded #267 · C

Strengths

  • Branded, FDA-approved GLP-1s — Wegovy, Ozempic, Zepbound, Mounjaro and Saxenda — rather than compounded copies
  • The membership band is published before intake and is banded openly by level of coach support
  • Medical visits, daily monitoring and 1-on-1 coaching are included in the membership at every tier
  • Led by CMO Dr. Henry Legere (UC Berkeley, Columbia medicine, Harvard fellowship)
  • Members with commercial insurance may pay around $25 a month for the medication after any deductible

Where it loses points

  • The membership is overhead, not a medication price: it covers visits, monitoring and coaching, and the FAQ says medication pricing is confirmed only after a provider consultation
  • No self-pay drug price is published anywhere, so the cost of a month cannot be worked out before signing up
  • The best case depends on commercial insurance coverage; without it the medication cost is unknown
  • No compounded option is disclosed — the programme is brand-focused, and brand list prices are the dearest route to a GLP-1
  • The states it can prescribe in are not published
KERNX Health

Graded #276 · C

Strengths

  • Publishes plan pricing openly, before any intake or account creation
  • Month-to-month with no long-term contract and no multi-month prepayment
  • Billing starts only after a licensed provider approves treatment
  • LegitScript certification verified against the issued seal, not just the badge

Where it loses points

  • Its own pricing page contradicts itself: it claims no separate consultation charges, then states a $25-$60 fee applies per visit
  • The consultation fee is charged whether or not a prescription is issued
  • Advertised $129 and $199 rates are time-limited founding rates; standard rates are $249 and $299
  • No compounding pharmacy is named anywhere on the site
  • Shipping claims conflict: a 48-hour figure on the homepage against 1-2 days to ship plus 2-3 days transit in the FAQ

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard